Joele Frank handled media for Teva Pharmaceutical Industries' July 27 $40B acquisition of Allergan Generics and same-day termination of its $40B hostile bid to acquire Mylan NV.

Jerusalem-based Teva said it talked to many investors about the future of the generics industry since the April 21 announcement of its plan to acquire Mylan.

Based on those conversations, the company believes swapping Mylan for Allergan is in the best interests of shareholders.

Regarding its 4.6 percent stake in Mylan, Teva is reviewing its options.

Teva lauded Allergan for its "world-class generics pipeline, which holds a leading position in first-to-file opportunities in the US."

Joele Frank and Tim Lynch worked both deals for Teva.